Structural basis of polyethylene glycol recognition by antibody.
Crown ether
Dimer formation
PEG-fab complex
Protein-protein interaction
X-ray crystallography
Journal
Journal of biomedical science
ISSN: 1423-0127
Titre abrégé: J Biomed Sci
Pays: England
ID NLM: 9421567
Informations de publication
Date de publication:
07 Jan 2020
07 Jan 2020
Historique:
received:
12
09
2019
accepted:
18
11
2019
entrez:
8
1
2020
pubmed:
8
1
2020
medline:
5
6
2020
Statut:
epublish
Résumé
Polyethylene glycol (PEG) is widely used in industry and medicine. Anti-PEG antibodies have been developed for characterizing PEGylated drugs and other applications. However, the underlying mechanism for specific PEG binding has not been elucidated. The Fab of two cognate anti-PEG antibodies 3.3 and 2B5 were each crystallized in complex with PEG, and their structures were determined by X-ray diffraction. The PEG-Fab interactions in these two crystals were analyzed and compared with those in a PEG-containing crystal of an unrelated anti-hemagglutinin 32D6-Fab. The PEG-binding stoichiometry was examined by using analytical ultracentrifuge (AUC). A common PEG-binding mode to 3.3 and 2B5 is seen with an S-shaped core PEG fragment bound to two dyad-related Fab molecules. A nearby satellite binding site may accommodate parts of a longer PEG molecule. The core PEG fragment mainly interacts with the heavy-chain residues D31, W33, L102, Y103 and Y104, making extensive contacts with the aromatic side chains. At the center of each half-circle of the S-shaped PEG, a water molecule makes alternating hydrogen bonds to the ether oxygen atoms, in a similar configuration to that of a crown ether-bound lysine. Each satellite fragment is clamped between two arginine residues, R52 from the heavy chain and R29 from the light chain, and also interacts with several aromatic side chains. In contrast, the non-specifically bound PEG fragments in the 32D6-Fab crystal are located in the elbow region or at lattice contacts. The AUC data suggest that 3.3-Fab exists as a monomer in PEG-free solution but forms a dimer in the presence of PEG-550-MME, which is about the size of the S-shaped core PEG fragment. The differing amino acids in 3.3 and 2B5 are not involved in PEG binding but engaged in dimer formation. In particular, the light-chain residue K53 of 2B5-Fab makes significant contacts with the other Fab in a dimer, whereas the corresponding N53 of 3.3-Fab does not. This difference in the protein-protein interaction between two Fab molecules in a dimer may explain the temperature dependence of 2B5 in PEG binding, as well as its inhibition by crown ether.
Sections du résumé
BACKGROUND
BACKGROUND
Polyethylene glycol (PEG) is widely used in industry and medicine. Anti-PEG antibodies have been developed for characterizing PEGylated drugs and other applications. However, the underlying mechanism for specific PEG binding has not been elucidated.
METHODS
METHODS
The Fab of two cognate anti-PEG antibodies 3.3 and 2B5 were each crystallized in complex with PEG, and their structures were determined by X-ray diffraction. The PEG-Fab interactions in these two crystals were analyzed and compared with those in a PEG-containing crystal of an unrelated anti-hemagglutinin 32D6-Fab. The PEG-binding stoichiometry was examined by using analytical ultracentrifuge (AUC).
RESULTS
RESULTS
A common PEG-binding mode to 3.3 and 2B5 is seen with an S-shaped core PEG fragment bound to two dyad-related Fab molecules. A nearby satellite binding site may accommodate parts of a longer PEG molecule. The core PEG fragment mainly interacts with the heavy-chain residues D31, W33, L102, Y103 and Y104, making extensive contacts with the aromatic side chains. At the center of each half-circle of the S-shaped PEG, a water molecule makes alternating hydrogen bonds to the ether oxygen atoms, in a similar configuration to that of a crown ether-bound lysine. Each satellite fragment is clamped between two arginine residues, R52 from the heavy chain and R29 from the light chain, and also interacts with several aromatic side chains. In contrast, the non-specifically bound PEG fragments in the 32D6-Fab crystal are located in the elbow region or at lattice contacts. The AUC data suggest that 3.3-Fab exists as a monomer in PEG-free solution but forms a dimer in the presence of PEG-550-MME, which is about the size of the S-shaped core PEG fragment.
CONCLUSIONS
CONCLUSIONS
The differing amino acids in 3.3 and 2B5 are not involved in PEG binding but engaged in dimer formation. In particular, the light-chain residue K53 of 2B5-Fab makes significant contacts with the other Fab in a dimer, whereas the corresponding N53 of 3.3-Fab does not. This difference in the protein-protein interaction between two Fab molecules in a dimer may explain the temperature dependence of 2B5 in PEG binding, as well as its inhibition by crown ether.
Identifiants
pubmed: 31907057
doi: 10.1186/s12929-019-0589-7
pii: 10.1186/s12929-019-0589-7
pmc: PMC6945545
doi:
Substances chimiques
Antibodies, Monoclonal, Murine-Derived
0
Immunoglobulin Fab Fragments
0
Polyethylene Glycols
3WJQ0SDW1A
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
12Subventions
Organisme : Ministry of Science and Technology
ID : MOST 108-3114-Y-001-002
Organisme : Academia Sinica
ID : AS-SUMMIT-108
Organisme : Technology Supporting Platform Axis
ID : AS-KPQ-106-TSPA
Organisme : Taiwan Protein Project
ID : AS-KPQ-105-TPP
Références
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):235-42
pubmed: 21460441
Anticancer Res. 2014 Dec;34(12):7319-26
pubmed: 25503167
Nat Biotechnol. 2004 Jan;22(1):93-7
pubmed: 14661026
Bioconjug Chem. 2005 Sep-Oct;16(5):1225-31
pubmed: 16173802
Methods Enzymol. 1997;276:307-26
pubmed: 27754618
Bioconjug Chem. 2013 Aug 21;24(8):1408-13
pubmed: 23837865
Bioconjug Chem. 2010 Jul 21;21(7):1264-70
pubmed: 20536171
Nat Rev Drug Discov. 2003 Mar;2(3):214-21
pubmed: 12612647
J Mol Biol. 2007 Jun 8;369(3):696-709
pubmed: 17445828
Clin Exp Allergy. 2016 Jul;46(7):907-22
pubmed: 27196817
Nat Commun. 2017 Jun 08;8:15507
pubmed: 28593948
Protein Sci. 2018 Jan;27(1):293-315
pubmed: 29067766
Anal Chem. 2016 Dec 20;88(24):12371-12379
pubmed: 28193011
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
N Engl J Med. 2007 Jul 19;357(3):239-50
pubmed: 17634459
Sci Rep. 2019 Mar 14;9(1):4546
pubmed: 30872685
J Mol Biol. 2004 Mar 26;337(3):691-7
pubmed: 15019787
Curr Opin Chem Biol. 2018 Jun;44:75-86
pubmed: 29908451
Nature. 1992 Nov 26;360(6402):369-72
pubmed: 1448155
Acta Crystallogr D Biol Crystallogr. 2013 Oct;69(Pt 10):1935-45
pubmed: 24100313
Biomaterials. 2014 Dec;35(37):9930-9940
pubmed: 25212525
MAbs. 2016 Jul;8(5):928-40
pubmed: 27031922
Lancet. 2001 Sep 22;358(9286):958-65
pubmed: 11583749
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Angew Chem Int Ed Engl. 2014 Nov 24;53(48):13054-8
pubmed: 25287606
Structure. 2006 Feb;14(2):205-16
pubmed: 16472740
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Bioconjug Chem. 1999 May-Jun;10(3):520-8
pubmed: 10346886
Molecules. 2015 Jun 23;20(6):11569-603
pubmed: 26111183
MAbs. 2014 Jul-Aug;6(4):1069-83
pubmed: 24874693
MAbs. 2017 Aug/Sep;9(6):916-926
pubmed: 28590212
Mol Cancer Ther. 2015 Jun;14(6):1317-26
pubmed: 25852063